Transcriptomics

Dataset Information

0

Spatially resolved whole-transcriptomic and proteomic profiling of lung cancer and immune-microenvironment according to PD-L1 expression


ABSTRACT: The expression of PD-L1 on tumor cells (TCs) is used as an immunotherapy biomarker in lung cancer, but heterogeneous intratumoral expression is often observed. Using a Digital Spatial Profiler, we performed proteomic and whole-transcriptomic analyses of TCs and immune cells (ICs) in spatially matched areas according to tumor PD-L1 expression and the status of the immune microenvironment. Several findings were validated using immunohistochemistry, The Cancer Genome Atlas, and immunotherapy cohorts. ICs in areas with high PD-L1 expression showed more features indicative of immunosuppression and exhaustion than ICs in areas with low PD-L1 expression. TCs highly expressing PD-L1 within immune-inflamed (IF) areas show up-regulation of pro-inflammatory processes, whereas TCs highly expressing PD-L1 within immune-deficient (ID) areas show up-regulation of various metabolic processes. Using differentially expressed genes of TCs between the IF and ID areas, we identified a novel prognostic gene signature for lung cancer. In addition, the high ratio of CD8+ cells to M2 macrophages was found to predict favorable outcomes in patients with PD-L1-expressing lung cancer after immune checkpoint inhibitor therapy. This study demonstrates that TCs and ICs have distinct spatial features within the tumor microenvironment that are related to tumoral PD-L1 expression and IC infiltration.

ORGANISM(S): Homo sapiens

PROVIDER: GSE265899 | GEO | 2024/08/21

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2020-06-22 | PXD019061 | panorama
2024-01-08 | PXD044086 | Pride
2021-09-27 | GSE180347 | GEO
2020-02-01 | GSE129968 | GEO
2012-07-09 | E-GEOD-39205 | biostudies-arrayexpress
2023-06-28 | GSE210884 | GEO
2012-07-09 | E-GEOD-39204 | biostudies-arrayexpress
2022-03-31 | MSV000089180 | MassIVE
2022-02-18 | GSE192591 | GEO
2022-02-17 | PXD026447 | Pride